{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:03:46Z","timestamp":1789488226751,"version":"build-2803163510"},"reference-count":83,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, such as the International Consensus Classification (ICC) and the WHO 2022 classification, have incorporated molecular and cytogenetic markers to improve the stratification of risk and guide therapy. However, treatment options for high-risk MDS (HR-MDS) remain limited, with hypomethylating agents (HMAs) providing only modest survival benefits. Emerging treatments such as immune checkpoint blockade and novel targeted therapies could further improve patient outcomes. While early excitement was significant, clinical trials of the immune checkpoint inhibitors (ICIs) ipilimumab and durvalumab have produced no definitive results, highlighting the need for better patient selection and combination regimens. Emerging drugs luspatercept and imetelstat have been suggested for lower-risk MDS (LR-MDS) by promoting transfusion independence and global hematologic response. In contrast, exploratory agents such as pevonedistat, magrolimab, and sabatolimab are under further investigation for HR-MDS. The future of MDS treatment currently addresses precision medicine, in which molecular characterization guides therapeutic options. Identification of predictive biomarkers for response to targeted therapies and immunotherapies is crucial to optimize patient outcomes. An integrated, patient-centered approach combining genomics, novel therapeutics, and immunomodulation is therefore essential to address the current needs in MDS management.<\/jats:p>","DOI":"10.46989\/001c.142956","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T11:42:57Z","timestamp":1754566977000},"source":"Crossref","is-referenced-by-count":4,"title":["Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches"],"prefix":"10.46989","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8764-9218","authenticated-orcid":true,"given":"Viviana","family":"Cortiana","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshitha","family":"Vallabhaneni","sequence":"additional","affiliation":[{"name":"Apollo Institute of Medical Sciences and Research, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Ghazal","sequence":"additional","affiliation":[{"name":"Kalamazoo Valley Community College, Kalamazoo, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Itodo","sequence":"additional","affiliation":[{"name":"Nigerian Institute Ffor Trypanosomiasis Research, Jos, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Kassim Dohadwala","sequence":"additional","affiliation":[{"name":"David Tvildiani Medical University, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Park","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute, Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Leyfman","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Hospital, Brooklyn, NY, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41375-024-02157-2","article-title":"The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the D\u00fcsseldorf MDS Registry and proposals for a merged classification","volume":"38","author":"K. Nachtkamp","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"ref2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: An analysis of 3307 cases","volume":"31","author":"A. Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"e467","DOI":"10.1016\/j.clml.2022.01.002","article-title":"Therapeutic outcomes and prognostic impact of gene mutations including TP53 and SF3B1 in patients with del(5q) myelodysplastic syndromes (MDS)","volume":"22","author":"O. Chan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.17925\/EOH.2007.0.0.30","article-title":"Review of the response criteria for myelodysplastic syndrome","volume":"30","author":"A. P. Conley","year":"2007","journal-title":"Eur Oncol Haematol"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"B. D. Cheson","year":"2006","journal-title":"Blood"},{"issue":"12","key":"ref6","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"M. R. Savona","year":"2015","journal-title":"Blood"},{"issue":"3","key":"ref7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PPO.0000000000000666","article-title":"Evolution of therapeutic benefit measurement criteria in myelodysplastic syndromes\/neoplasms","volume":"29","author":"J. M. Stempel","year":"2023","journal-title":"Cancer J"},{"issue":"2","key":"ref8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"P. Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-140284","article-title":"The COMMANDS Trial: A phase 3 study of the efficacy and safety of luspatercept versus epoetin alfa for the treatment of anemia due to IPSS-R very low-, low-, or intermediate-risk MDS in erythropoiesis stimulating agent-naive patients who require RBC transfusions","volume":"136","author":"M. Della Porta","year":"2020","journal-title":"Blood"},{"issue":"16 suppl","key":"ref10","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1200\/jco.2023.41.16_suppl.7004","article-title":"IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed\/refractory (R\/R) to erythropoiesis stimulating agents (ESA)","volume":"41","author":"A. M. Zeidan","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref11","article-title":"Immune checkpoint inhibition and novel therapies for myelodysplastic syndromes\/neoplasms","author":"A. Zeidan","year":"2023","journal-title":"Proceedings of the MedNews Week Keynote Conference"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/PPO.0000000000000658","article-title":"Novel approaches and future directions in myelodysplastic syndrome treatment","volume":"29","author":"J. P. Bewersdorf","year":"2023","journal-title":"Cancer J"},{"issue":"7","key":"ref13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"A. M. Zeidan","year":"2018","journal-title":"Blood"},{"issue":"6","key":"ref14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-018-0081-8","article-title":"Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: Are we using realistic estimates?","volume":"8","author":"A. M. Zeidan","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"ref15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bjh.14407","article-title":"A phase 2 trial of high dose lenalidomide in patients with relapsed\/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia","volume":"176","author":"A. M. Zeidan","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"ref16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2021-145646","article-title":"Venetoclax and azacitidine in the treatment of patients with relapsed\/refractory myelodysplastic syndrome","volume":"138","author":"A. M. Zeidan","year":"2021","journal-title":"Blood"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"A. M. Zeidan","year":"2023","journal-title":"Am J Hematol"},{"issue":"21","key":"ref18","doi-asserted-by":"publisher","first-page":"e120974","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"H. A. Knaus","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"ref19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"M. S. Davids","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"ref20","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"A. M. Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ref21","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"A. M. Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"ref22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40266-021-00881-3","article-title":"Management of the older patient with myelodysplastic syndrome","volume":"38","author":"R. M. Shallis","year":"2021","journal-title":"Drugs Aging"},{"issue":"15","key":"ref23","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"S.X. Lu","year":"2021","journal-title":"Cell"},{"issue":"suppl 1","key":"ref24","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.1182\/blood-2022-158592","article-title":"Impact of allelic state on overall survival in TP53-mutant acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)","volume":"140","author":"J. P. Bewersdorf","year":"2022","journal-title":"Blood"},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00277-023-05552-4","article-title":"A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes\/neoplasms or acute myeloid leukemia refractory to hypomethylating agents","volume":"103","author":"J. P. Bewersdorf","year":"2024","journal-title":"Ann Hematol"},{"issue":"6","key":"ref26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"M. A. Sekeres","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"ref27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1182\/blood-2018-99-119259","article-title":"Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (pts) with higher-risk (HR) myelodysplastic syndromes (MDS): Efficacy and safety results in HMA treatment na\u00efve & relapsed (Rel)\/refractory (Ref) patients","volume":"132","author":"S.C. Navada","year":"2018","journal-title":"Blood"},{"issue":"2","key":"ref28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3324\/haematol.2023.284946","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"N. Kr\u00f6ger","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"S. Schwartz","year":"2022","journal-title":"Immunother Adv"},{"issue":"suppl 1","key":"ref30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-134718","article-title":"The STIMULUS Program: Clinical trials evaluating sabatolimab (MBG453) combination therapy in patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML)","volume":"136","author":"A. M. Zeidan","year":"2020","journal-title":"Blood"},{"issue":"1","key":"ref31","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"A. M. Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"ref32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: A phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"A. M. Zeidan","year":"2023","journal-title":"Future Oncol"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ajcp\/aqaa046","article-title":"How I diagnose low-grade myelodysplastic syndromes","volume":"154","author":"A. J. Siddon","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"7239","key":"ref34","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"T. A. Soucy","year":"2009","journal-title":"Nature"},{"issue":"7","key":"ref35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1947601910382898","article-title":"The NEDD8 conjugation pathway and its relevance in cancer biology and therapy","volume":"1","author":"T. A. Soucy","year":"2010","journal-title":"Genes Cancer"},{"issue":"7","key":"ref36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"M. A. Sekeres","year":"2021","journal-title":"Leukemia"},{"issue":"17","key":"ref37","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"L. Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"ref38","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3390\/curroncol31040148","article-title":"Myelodysplastic neoplasms (MDS): The current and future treatment landscape","volume":"31","author":"D. Karel","year":"2024","journal-title":"Curr Oncol"},{"issue":"14","key":"ref39","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"D. A. Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"J. E. Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"ref41","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial","volume":"17","author":"G. Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"ref42","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1182\/blood-2018-99-118463","article-title":"Amelioration of rigosertib treatment-related genitourinary (GU) adverse events (AEs) in patients with myelodysplastic syndromes: Implementation of novel dosing regimen derived through pharmacokinetic modeling in phase 2 study of oral rigosertib in combination with azacitidine","volume":"132","author":"D. Taft","year":"2018","journal-title":"Blood"},{"issue":"15","key":"ref43","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: Final results of a phase Ib study","volume":"41","author":"D. A. Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref44","article-title":"Myelodysplastic Syndromes Risk Factors | American Cancer Society","journal-title":"American Cancer Society"},{"issue":"15 suppl","key":"ref45","doi-asserted-by":"publisher","first-page":"TPS7055","DOI":"10.1200\/jco.2021.39.15_suppl.tps7055","article-title":"Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study","volume":"39","author":"G. Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"ref46","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood-2018-99-111285","article-title":"Early results from a biomarker-directed phase 2 trial of Sy-1425 in combination with azacitidine or daratumumab in non-APL acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"132","author":"R. J. Cook","year":"2018","journal-title":"Blood"},{"issue":"9","key":"ref47","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA overexpression with tamibarotene, a potent and selective RAR\u03b1 agonist, is a novel approach in AML","volume":"7","author":"S. de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"ref48","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1016\/S2152-2650(22)01395-7","article-title":"MDS-110 SELECT-MDS-1 Trial in progress: A phase 3 randomized, double-blind, placebo-controlled study of tamibarotene\/azacitidine versus placebo\/azacitidine in newly diagnosed adult patients selected for RARA-positive higher-risk MDS","volume":"22","author":"A. DeZern","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"ref49","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1080\/10428194.2022.2034155","article-title":"Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study","volume":"63","author":"G. Garcia-Manero","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"ref50","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"K. S. Chien","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"ref51","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"M. S. Davids","year":"2020","journal-title":"Blood"},{"issue":"7","key":"ref52","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"A. M. Zeidan","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"ref53","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"A. M. Zeidan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"994053","DOI":"10.3389\/fimmu.2022.994053","article-title":"The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification","volume":"13","author":"X. Peng","year":"2022","journal-title":"Front Immunol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"101001","DOI":"10.1016\/j.blre.2022.101001","article-title":"CHIPing away the progression potential of CHIP: A new reality in the making","volume":"58","author":"Z. Xie","year":"2023","journal-title":"Blood Rev"},{"issue":"suppl 1","key":"ref56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2018-99-119424","article-title":"A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)","volume":"132","author":"G. Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"ref57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-136566","article-title":"The combination of AXL inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II Trial (NCT02488408)","volume":"136","author":"S. Loges","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"ref58","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood-2018-99-119805","article-title":"A clinical study of tomaralimab (OPN-305), a Toll-like receptor 2 (TLR-2) antibody, in heavily pre-treated transfusion dependent patients with lower risk myelodysplastic syndromes (MDS) that have received and failed on prior hypomethylating agent (HMA) therapy","volume":"132","author":"G. Garcia-Manero","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"ref59","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1182\/blood.v130.suppl_1.1917.1917","article-title":"Anti-CD123 CAR T-cell therapy for the treatment of myelodysplastic syndrome","volume":"130","author":"W. Zhang","year":"2017","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"108467","DOI":"10.1016\/j.clim.2020.108467","article-title":"Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on dendritic cells of leukemic origin (DCleu)","volume":"217","author":"C. Ansprenger","year":"2020","journal-title":"Clin Immunol"},{"issue":"8","key":"ref61","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"A. T. Bj\u00f6rklund","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref62","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for Cancer Immunotherapy","volume":"16","author":"Linyuan, et al. Cai","year":"2023","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"ref63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid Immunosuppression and Immune Checkpoints in the Tumor Microenvironment","volume":"17","author":"Kyohei Nakamura","year":"2019","journal-title":"Cellular & Molecular Immunology"},{"issue":"17","key":"ref64","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus Azacitidine vs Azacitidine Alone in Higher-Risk MDS\/Chronic Myelomonocytic Leukemia or Low-Blast-Percentage AML","volume":"6","author":"Lionel, et al. Ad\u00e8s","year":"2022","journal-title":"Blood Advances"},{"issue":"6","key":"ref65","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.tranon.2018.08.009","article-title":"The Mutant P53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells","volume":"11","year":"2018","journal-title":"Translational Oncology"},{"issue":"25","key":"ref66","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"L. Malcovati","year":"2017","journal-title":"Blood"},{"issue":"10","key":"ref67","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1158\/1078-0432.ccr-17-2824","article-title":"Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS","volume":"24","author":"Michael R., et al. Savona","year":"2018","journal-title":"Clinical Cancer Research"},{"issue":"4","key":"ref68","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/s1470-2045(16)00009-7","article-title":"Rigosertib versus Best Supportive Care for Patients with High-Risk Myelodysplastic Syndromes after Failure of Hypomethylating Drugs (ONTIME): A Randomised, Controlled, Phase 3 Trial","volume":"17","author":"Guillermo, et al. Garcia-Manero","year":"2016"},{"issue":"15","key":"ref69","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3390\/cancers15153815","article-title":"Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic\/Myeloproliferative Neoplasms","volume":"15","author":"Margo Brooke, et al. Gerke","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"ref70","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/bloodadvances.2022008806","article-title":"Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RAR\u03b1 Agonist, Is a Novel Approach in AML","volume":"7","author":"St\u00e9phane, et al. de Botton","year":"2023","journal-title":"Blood Advances"},{"issue":"10","key":"ref71","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 Allelic State for Genome Stability, Clinical Presentation, and Outcomes in Myelodysplastic Syndromes","volume":"26","author":"E. Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"14","key":"ref72","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.01978","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes","volume":"39","author":"D. A. Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref73","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1038\/s41375-021-01236-3","article-title":"Current Challenges and Unmet Medical Needs in Myelodysplastic Syndromes","volume":"35","author":"U. Platzbecker","year":"2021","journal-title":"Leukemia"},{"issue":"15","key":"ref74","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts","volume":"365","author":"E. Papaemmanuil","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"ref75","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"P. Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"ref76","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.3324\/haematol.2021.279235","article-title":"Luspatercept for Anemia in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"106","author":"R. S. Komrokji","year":"2021","journal-title":"Haematologica"},{"issue":"21","key":"ref77","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"C. A. Cargo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"ref78","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01520-1","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"J. D. Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"ref79","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1182\/blood-2011-03-341784","article-title":"Prognostic Value of TET2 Mutations in Low-Risk Myelodysplastic Syndromes","volume":"118","author":"R. Itzykson","year":"2011","journal-title":"Blood"},{"issue":"2","key":"ref80","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of Genetic Lesions in 944 Patients with Myelodysplastic Syndromes","volume":"28","author":"T. Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"ref81","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399345","article-title":"Frequency and Prognostic Impact of Mutations in SRSF2, U2AF1, and ZRSR2 in Patients with Myelodysplastic Syndromes","volume":"119","author":"F. Thol","year":"2012","journal-title":"Blood"},{"issue":"6","key":"ref82","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.3390\/ijms24065734","article-title":"The genetic landscape of myelodysplastic neoplasm progression to acute myeloid leukemia","volume":"24","author":"C. B\u0103nescu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41408-024-01031-9","article-title":"Comparison of the 2022 World Health Organization classification and International Consensus Classification in myelodysplastic syndromes\/neoplasms","volume":"14","author":"W. H. Lee","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/142956-beyond-hypomethylating-agents-novel-therapies-and-targeted-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:17:35Z","timestamp":1789485455000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/142956-beyond-hypomethylating-agents-novel-therapies-and-targeted-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":83,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.142956","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}